Evommune shares plunge after eczema drug EVO756 fails mid-stage goals
Evommune (EVMN) shares fell more than 15% in extended trading after it said lead candidate EVO756 failed to meet main goals in a mid-stage eczema trial, citing topline data.
Evommune NYSE:EVMN shares fell more than 15% in extended trading on Wednesday after the company said its lead candidate, EVO756, missed its main goals in a mid-stage eczema trial. The Palo Alto, California-based biotech cited topline data.